Royalty Pharma Declares Fourth Quarter 2025 Dividend
Royalty Pharma (Nasdaq: RPRX) announced a fourth-quarter 2025 dividend of $0.22 per Class A ordinary share. The board approved the dividend to shareholders of record at the close of business on November 14, 2025, with payment scheduled for December 10, 2025.
This provides a cash distribution to holders of Class A ordinary shares in Q4 2025 and sets clear record and payment dates for investors.
Royalty Pharma (Nasdaq: RPRX) ha annunciato un dividendo del quarto trimestre 2025 di 0,22 USD per azione ordinaria di Classe A. Il consiglio ha approvato il dividendo per gli azionisti registrati alla chiusura degli affari del 14 novembre 2025, con pagamento previsto per 10 dicembre 2025.
Questo offre una distribuzione in contanti agli detentori di azioni ordinarie di Classe A nel Q4 2025 e stabilisce date di registrazione e pagamento chiare per gli investitori.
Royalty Pharma (Nasdaq: RPRX) anunció un dividendo del cuarto trimestre de 2025 de $0.22 por acción ordinaria de Clase A. La Junta aprobó el dividendo para los accionistas registrados al cierre de operaciones el 14 de noviembre de 2025, con pago programado para el 10 de diciembre de 2025.
Esto proporciona una distribución en efectivo a los titulares de acciones ordinarias de Clase A en el Q4 2025 y establece fechas claras de registro y pago para los inversores.
Royalty Pharma (Nasdaq: RPRX)는 2025년 4분기 배당금을 주당 클래스 A 보통주 1주당 0.22달러로 발표했습니다. 이사회는 2025년 11월 14일 영업 종료 시점에 등재된 주주를 대상으로 배당금을 승인했으며, 지급은 2025년 12월 10일로 예정되어 있습니다.
이는 2025년 4분기에 클래스 A 보통주 보유자에게 현금 분배를 제공하고 투자자들을 위한 명확한 등록 및 지급일을 설정합니다.
Royalty Pharma (NASDAQ: RPRX) a annoncé un dividende pour le quatrième trimestre 2025 de 0,22 USD par action ordinaire de classe A. Le conseil a approuvé le dividende pour les actionnaires enregistrés à la fermeture des marchés le 14 novembre 2025, avec un paiement prévu le 10 décembre 2025.
Cela offre une distribution en espèces aux détenteurs d'actions ordinaires de classe A au T4 2025 et établit des dates d'enregistrement et de paiement claires pour les investisseurs.
Royalty Pharma (Nasdaq: RPRX) kündigte eine Dividende für das vierte Quartal 2025 in Höhe von 0,22 USD pro Class-A-Stammaktie an. Der Vorstand hat die Dividende für Aktionäre genehmigt, die am Geschäftsschluss am 14. November 2025 registriert sind, mit Auszahlung am 10. Dezember 2025.
Dies bietet eine Barauszahlung an Inhaber von Class-A-Stammaktien im Q4 2025 und setzt klare Aufzeichnungs- und Zahlungsfristen für Investoren fest.
Royalty Pharma (ناسداك: RPRX) أعلنت عن توزيع أرباح للربع الرابع من 2025 بقيمة 0.22 دولارًا أمريكيًا للسهم العادي من الفئة أ. وافق المجلس على التوزيع للمساهمين المسجَّلين بنهاية دوام العمل في 14 نوفمبر 2025، وموعد الدفع محدد ليكون 10 ديسمبر 2025.
هذا يوفر توزيعًا نقديًا لمالكي الأسهم العادية من الفئة أ في الربع الرابع من 2025 ويحدد تواريخ التسجيل والدفع بشكل واضح للمستثمرين.
Royalty Pharma（纳斯达克股票代码：RPRX） 宣布了2025年第四季度的股息，金额为每股A类普通股 0.22 美元。董事会已批准在 2025年11月14日营业结束时登记在册的股东享有股息，支付日期定于 2025年12月10日。
这为2025年第四季度的A类普通股持有者提供现金分配，并为投资者设定了明确的登记和支付日期。
- $0.22 per Class A share dividend
- Payment scheduled on December 10, 2025
- Record date set at November 14, 2025
- Provides direct cash income to shareholders
- Creates a company cash outflow on December 10, 2025
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of
The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What dividend did Royalty Pharma (RPRX) declare for Q4 2025?
When will Royalty Pharma (RPRX) pay the Q4 2025 dividend?
What is the record date for Royalty Pharma's (RPRX) Q4 2025 dividend?
Who is eligible to receive Royalty Pharma's (RPRX) December 10, 2025 dividend?
How much cash will Royalty Pharma (RPRX) distribute per share for Q4 2025?
